

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ELI LILLY AND COMPANY,  
Petitioner,

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH,  
Patent Owner.

---

Case IPR2018-01422 (Patent 9,340,614 B2)  
Case IPR2018-01423 (Patent 9,266,951 B2)  
Case IPR2018-01424 (Patent 9,346,881 B2)  
Case IPR2018-01425 (Patent 9,890,210 B2)  
Case IPR2018-01426 (Patent 9,890,211 B2)  
Case IPR2018-01427 (Patent 8,597,649 B2)<sup>1</sup>

---

**PATENT OWNER'S DEMONSTRATIVES**

---

<sup>1</sup> A word-for-word identical copy of this paper is filed in each proceeding identified in the caption.



2018-01422  
2018-01423  
2018-01424  
2018-01425  
2018-01426  
2018-01427



---

Eli Lilly and Company  
v.  
Teva Pharmaceuticals International GmbH

---

November 22, 2019

## A POSA would not have had a reason to humanize anti-CGRP antibodies with a reasonable expectation of success

POR, 4-5, 10-12, 19-22, 36-40, 46-51

### Tan 1995's full-length antibody did not achieve immunoblockade:

- “only the Fab’ fragment was found to be an effective tool for blockade ” in rats. EX1022, 570; POR, 39; EX2054, ¶51.

### Wimalawansa's reference to anti-CGRP antibodies is inconclusive:

- “Clearly, more data from carefully designed studies are necessary before any definitive conclusions can be reached and before CGRP antagonist, **humanized anti-CGRP monoclonal antibodies**, or both, can be evaluated as therapeutic agents in humans.” EX1096, 567; POR, 4, 7, 10-11, 19-22; EX2137, ¶¶80-85; EX2054, ¶¶56-59; EX2141, ¶¶25, 72.
- “These data warrant further studies in an animal model of sepsis to determine whether **blocking CGRP receptors with specific antagonists or monoclonal antibodies** has beneficial effects on the outcome.” EX1096, 568; POR, 10-11, 49; EX2054, ¶158; EX2241, ¶86.

### The decade between Tan/Wimalawansa and Teva's invention:

- Salmon, Sveinsson, and the '438 patent mention anti-CGRP antibodies in passing and provide no data. POR, 34-36; EX1026, 7:19; EX1027, ¶[0038]; EX1028, 2:17-55.

## Before Teva's invention, the industry focused on receptor antagonists and triptans

POR, 10-11, 49

### Wimalawansa:

- “CGRP antagonists can be used in the late phase [of migraine]. However, ***the antagonist must be extremely specific to the CGRP receptors*** located in cerebral arteries to avoid potential deleterious side effects caused by blocking other vascular and nonvascular CGRP receptors.” EX1096, 568; POR, 11, 20, 49; Institution Decision, 15; EX2241, ¶186
- “These data warrant further studies in an animal model of sepsis to determine whether ***blocking CGRP receptors with specific antagonists or monoclonal antibodies*** has beneficial effects on the outcome.” EX1096, 568; POR, 10-11, 49; EX2054, ¶158

### Arulmani:

- “An important breakthrough in the field of CGRP receptors is the ***development of potent CGRP receptor antagonists.***” EX1031, 323; POR, 49; EX2141, ¶123

### Olesen:

- “BIBN 4096 BS is a nonpeptide ***CGRP-receptor antagonist*** with an extremely high affinity and specificity for the human CGRP receptor.” EX1025, 1105; POR, 49; EX2141, ¶122

### Arulmohzi:

- “The last decade has witnessed the ***advent of Sumatriptan and the ‘triptan’ class of 5-HT<sub>1B/1D</sub> receptor agonists*** which have well established efficacy in treating migraine.” EX1040, 176; POR, 49; EX2141, ¶121

## **Leva's invention led to breakthrough migraine therapy** POR, 52-56

### **Lilly admits that the claimed antibodies satisfied a long-felt, unmet need:**

- Humanized anti-CGRP antibodies are a: “[s]afe, effective and well tolerated treatment for the prevention of migraine” that satisfied this “enormous unmet medical need.” EX2161, 6; POR, 55-56; EX2165, ¶¶25-44

### **The Industry praised the claimed antibodies:**

- “an enormous step forward” EX2172, 1-2; POR, 52-55; EX2165, ¶150
- “a game changer” EX2179, 4; POR, 52-55; EX2165, ¶152
- a “breakthrough in migraine” EX2174 ,707; POR, 52-55; EX2165, ¶49

### **Lilly's expert, Dr. Charles, also praised the claimed antibodies as:**

- “radical concept” EX2053, 23; POR, 52-55; EX2165, ¶157
- “very exciting and compelling” EX2182, 207; POR, 9; EX2165, ¶157
- “absolutely life-changing” EX2186, 4; POR, 52-53; EX2165, ¶157
- “spectacular” EX2186, 4-5; POR, 52-53; EX2165, ¶157

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.